AustraliaHealth

Imagion Biosystems (ASX:IBX) achieved a regulatory milestone following formal Investigational New Drug clearance from the US FDA.

4DMedical (ASX:4DX) has launched CLEAR, a clinical evidence programme designed to fast-track its proprietary CT:VQ technology.

Memphasys (ASX:MEM) has secured its first commercial partnership in Southeast Asia.

ReNerve (ASX:RNV) entered an exclusive three-year deal with Swedish Trading to commercialise its NervAlign nerve repair products.

4DMedical (ASX:4DX) announced a binding agreement to acquire the Austrian-based medical technology company contextflow.

Pro Medicus (ASX:PME) has secured two major contract wins in the United States, totalling $44 million.

Paragon Care (ASX:PGC) issued an update regarding its financial exposure to the receivership of the Infinity Retail Pharmacy Group.

PolyNovo (ASX:PNV) has finalised the clinical study report for its US pivotal randomised controlled trial evaluating NovoSorb BTM for full-thickness burns.

4DMedical (ASX:4DX) has secured a commercial agreement with SimonMed Imaging.

Imugene (ASX:IMU) announced a milestone in its ongoing Phase 1b basket study of azer-cel.

Acrux (ASX:ACR) finalised an amendment to its licensing agreement with Gedeon Richter for the transdermal estradiol spray, Lenzetto.

Australian Clinical Labs (ASX:ACL) appointed Greg Horan as its new Group CEO and executive director.